10x Genomics Quarterly Income Statements Chart
Quarterly
|
Annual
10x Genomics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| products and services revenue | 145,157,000 | 137,823,000 | |||||||||||||||||||||
| license and royalty revenue | 27,751,000 | 17,060,000 | |||||||||||||||||||||
| revenue | 172,908,000 | 154,883,000 | 165,021,000 | 151,654,000 | 153,104,000 | 141,006,000 | 183,979,000 | 153,644,000 | 146,819,000 | 134,285,000 | 156,232,000 | 131,072,000 | 114,609,000 | 114,496,000 | 143,530,000 | 125,297,000 | 115,842,000 | 105,821,000 | 71,817,000 | 42,905,000 | 71,905,000 | 75,289,000 | 61,207,000 |
| yoy | 12.93% | 9.84% | -10.30% | -1.30% | 4.28% | 5.01% | 17.76% | 17.22% | 28.10% | 17.28% | 8.85% | 4.61% | -1.06% | 8.20% | 99.86% | 192.03% | 61.10% | 40.55% | 17.33% | ||||
| qoq | 11.64% | -6.14% | 8.81% | -0.95% | 8.58% | -23.36% | 19.74% | 4.65% | 9.33% | -14.05% | 19.20% | 14.36% | 0.10% | -20.23% | 14.55% | 8.16% | 9.47% | 47.35% | 67.39% | -40.33% | -4.49% | 23.01% | |
| cost of products and services revenue | 47,824,000 | 49,438,000 | |||||||||||||||||||||
| gross profit | 125,084,000 | 105,445,000 | 110,955,000 | 106,393,000 | 104,220,000 | 92,914,000 | 115,782,000 | 95,529,000 | 99,612,000 | 98,390,000 | 119,405,000 | 100,695,000 | 86,905,000 | 89,018,000 | 115,932,000 | 100,779,000 | 110,927,000 | 88,761,000 | 57,406,000 | 32,853,000 | 56,797,000 | 58,707,000 | 45,727,000 |
| yoy | 20.02% | 13.49% | -4.17% | 11.37% | 4.63% | -5.57% | -3.03% | -5.13% | 14.62% | 10.53% | 3.00% | -0.08% | -21.66% | 0.29% | 101.95% | 206.76% | 95.30% | 51.19% | 25.54% | ||||
| qoq | 18.62% | -4.97% | 4.29% | 2.09% | 12.17% | -19.75% | 21.20% | -4.10% | 1.24% | -17.60% | 18.58% | 15.87% | -2.37% | -23.22% | 15.04% | -9.15% | 24.97% | 54.62% | 74.74% | -42.16% | -3.25% | 28.39% | |
| gross margin % | 72.34% | 68.08% | 67.24% | 70.16% | 68.07% | 65.89% | 62.93% | 62.18% | 67.85% | 73.27% | 76.43% | 76.82% | 75.83% | 77.75% | 80.77% | 80.43% | 95.76% | 83.88% | 79.93% | 76.57% | 78.99% | 77.98% | 74.71% |
| operating expenses: | |||||||||||||||||||||||
| research and development | 61,224,000 | 64,245,000 | 66,968,000 | 66,174,000 | 62,918,000 | 68,638,000 | 65,267,000 | 66,507,000 | 71,460,000 | 67,098,000 | 63,614,000 | 67,290,000 | 70,685,000 | 64,078,000 | 61,885,000 | 54,582,000 | 53,402,000 | 41,883,000 | 30,143,000 | 27,535,000 | 25,992,000 | 27,889,000 | 22,209,000 |
| selling, general and administrative | 74,434,000 | 89,728,000 | 93,826,000 | 81,704,000 | 83,039,000 | 85,774,000 | 86,125,000 | 82,415,000 | 91,510,000 | 83,280,000 | 78,887,000 | 73,401,000 | 79,337,000 | 66,675,000 | 69,877,000 | 62,076,000 | 68,703,000 | 56,904,000 | 51,549,000 | 44,416,000 | 50,387,000 | 38,756,000 | 32,614,000 |
| gain on settlement | -40,700,000 | -9,200,000 | |||||||||||||||||||||
| total operating expenses | 94,958,000 | 144,773,000 | 160,794,000 | 147,878,000 | 145,957,000 | 154,412,000 | 170,970,000 | 190,324,000 | 162,970,000 | 150,378,000 | 142,501,000 | 140,691,000 | 150,022,000 | 130,753,000 | 131,762,000 | 116,658,000 | 121,255,000 | 98,977,000 | 122,661,000 | 72,273,000 | 76,681,000 | 66,787,000 | 54,823,000 |
| income from operations | 30,126,000 | -39,328,000 | -49,839,000 | -41,485,000 | -41,737,000 | -61,498,000 | -55,188,000 | -94,795,000 | -63,358,000 | -51,988,000 | -23,096,000 | -39,996,000 | -63,117,000 | -41,735,000 | -15,830,000 | -15,879,000 | -10,328,000 | -10,216,000 | -65,255,000 | -39,420,000 | -19,884,000 | -8,080,000 | -9,096,000 |
| yoy | -172.18% | -36.05% | -9.69% | -56.24% | -34.13% | 18.29% | 138.95% | 137.01% | 0.38% | 24.57% | 45.90% | 151.88% | 511.13% | 308.53% | -75.74% | -59.72% | -48.06% | 26.44% | 617.40% | ||||
| qoq | -176.60% | -21.09% | 20.14% | -0.60% | -32.13% | 11.43% | -41.78% | 49.62% | 21.87% | 125.10% | -42.25% | -36.63% | 51.23% | 163.64% | -0.31% | 53.75% | 1.10% | -84.34% | 65.54% | 98.25% | 146.09% | -11.17% | |
| operating margin % | 17.42% | -25.39% | -30.20% | -27.36% | -27.26% | -43.61% | -30.00% | -61.70% | -43.15% | -38.71% | -14.78% | -30.51% | -55.07% | -36.45% | -11.03% | -12.67% | -8.92% | -9.65% | -90.86% | -91.88% | -27.65% | -10.73% | -14.86% |
| other income: | |||||||||||||||||||||||
| interest income | 4,271,000 | 3,686,000 | 4,026,000 | 4,971,000 | 4,715,000 | 4,736,000 | 4,637,000 | 4,300,000 | 4,100,000 | 3,869,000 | 2,815,000 | 2,025,000 | 1,238,000 | 569,000 | 49,000 | 49,000 | 58,000 | 50,000 | 28,000 | 125,000 | 1,318,000 | 1,819,000 | 481,000 |
| interest expense | -3,000 | -2,000 | -1,000 | -1,000 | -8,000 | -1,000 | -5,000 | -19,000 | -125,000 | -114,000 | -109,000 | -128,000 | -217,000 | -219,000 | -209,000 | -221,000 | -397,000 | -306,000 | -662,000 | -992,000 | -708,000 | ||
| other income | 2,603,000 | 2,136,000 | -2,567,000 | 2,078,000 | -56,000 | -1,040,000 | 3,961,000 | -1,248,000 | -1,504,000 | -1,516,000 | 3,995,000 | -1,950,000 | -1,843,000 | -400,000 | 5,000 | -599,000 | 521,000 | -729,000 | 361,000 | -144,000 | |||
| total other income | 6,871,000 | 5,822,000 | 1,459,000 | 7,047,000 | 4,658,000 | 3,695,000 | 8,590,000 | 3,051,000 | 2,591,000 | 2,334,000 | 6,685,000 | -39,000 | -714,000 | 41,000 | -163,000 | -769,000 | 370,000 | -900,000 | -8,000 | -325,000 | -961,000 | 1,054,000 | -499,000 |
| income before benefit from income taxes | 36,997,000 | -33,506,000 | -48,380,000 | -34,438,000 | -37,079,000 | -57,803,000 | -46,598,000 | -91,744,000 | -60,767,000 | -49,654,000 | -16,411,000 | -40,035,000 | -63,831,000 | -41,694,000 | -15,993,000 | -16,648,000 | -9,958,000 | -11,116,000 | -65,263,000 | -39,745,000 | -20,845,000 | -7,026,000 | -9,595,000 |
| benefit from income taxes | 2,459,000 | 852,000 | 648,000 | 1,315,000 | 818,000 | 2,146,000 | 2,354,000 | 1,242,000 | 1,647,000 | 1,093,000 | 804,000 | 1,879,000 | 627,000 | 719,000 | 2,456,000 | 523,000 | 1,094,000 | 435,000 | 585,000 | 422,000 | 298,000 | 108,000 | 8,000 |
| net income | 34,538,000 | -34,358,000 | -49,028,000 | -35,753,000 | -37,897,000 | -59,949,000 | -48,952,000 | -92,986,000 | -62,414,000 | -50,747,000 | -17,215,000 | -41,914,000 | -64,458,000 | -42,413,000 | -18,449,000 | -17,171,000 | -11,052,000 | -11,551,000 | -65,848,000 | -40,167,000 | -21,143,000 | -7,134,000 | -9,603,000 |
| yoy | -191.14% | -42.69% | 0.16% | -61.55% | -39.28% | 18.13% | 184.36% | 121.85% | -3.17% | 19.65% | -6.69% | 144.10% | 483.22% | 267.18% | -71.98% | -57.25% | -47.73% | 61.91% | 585.70% | ||||
| qoq | -200.52% | -29.92% | 37.13% | -5.66% | -36.78% | 22.46% | -47.36% | 48.98% | 22.99% | 194.78% | -58.93% | -34.97% | 51.98% | 129.89% | 7.44% | 55.37% | -4.32% | -82.46% | 63.94% | 89.98% | 196.37% | -25.71% | |
| net income margin % | 19.97% | -22.18% | -29.71% | -23.58% | -24.75% | -42.52% | -26.61% | -60.52% | -42.51% | -37.79% | -11.02% | -31.98% | -56.24% | -37.04% | -12.85% | -13.70% | -9.54% | -10.92% | -91.69% | -93.62% | -29.40% | -9.48% | -15.69% |
| net income per share | 0.28 | -0.28 | -0.41 | -0.3 | -0.32 | -0.5 | -0.41 | -0.79 | -0.53 | -0.44 | -0.15 | -0.37 | -0.57 | -0.38 | -0.17 | -0.15 | -0.1 | -0.11 | -0.65 | -0.41 | -0.22 | 0.41 | -0.33 |
| weighted-average shares used for eps calculation | 123,755,409 | 122,606,091 | 120,451,550 | 117,165,036 | 113,858,684 | 110,347,937 | 39,091,366 | ||||||||||||||||
| cost of revenue | 54,066,000 | 45,261,000 | 48,884,000 | 48,092,000 | 68,197,000 | 58,115,000 | 47,207,000 | 35,895,000 | 36,827,000 | 30,377,000 | 27,704,000 | 25,478,000 | 27,598,000 | 24,518,000 | 4,915,000 | 17,060,000 | 14,411,000 | 10,052,000 | 15,108,000 | 16,582,000 | 15,480,000 | ||
| in-process research and development | 19,578,000 | 41,402,000 | 40,637,000 | ||||||||||||||||||||
| weighted-average shares of common stock used in computing net income per share, basic and diluted | 120,733,030 | 120,066,972 | 119,394,180 | 117,728,293 | 116,707,672 | 115,619,869 | 114,112,382 | 113,574,757 | 112,966,196 | 110,874,249 | 109,866,294 | 108,714,027 | 101,341,945 | 98,978,283 | 96,829,093 | ||||||||
| accrued contingent liabilities | -850,000 | 190,000 | 332,000 | 322,000 | 302,000 | 142,000 | |||||||||||||||||
| loss on extinguishment of debt | -1,521,000 | ||||||||||||||||||||||
| other comprehensive income: | |||||||||||||||||||||||
| foreign currency translation adjustment | -172,000 | 136,000 | 10,000 | 98,000 | -366,000 | 355,000 | 5,000 | 114,000 | -126,000 | ||||||||||||||
| comprehensive loss | -18,621,000 | -17,035,000 | -11,042,000 | -11,453,000 | -66,214,000 | -39,812,000 | -21,138,000 | -7,020,000 | -9,729,000 | ||||||||||||||
| other incomes | -96,000 | -103,250 | -272,000 | ||||||||||||||||||||
| weighted-average shares of common stock used in computing net income per share attributable to common stockholders, basic and diluted | 29,184,218 |
We provide you with 20 years income statements for 10x Genomics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of 10x Genomics stock. Explore the full financial landscape of 10x Genomics stock with our expertly curated income statements.
The information provided in this report about 10x Genomics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.